Therefore, we investigated the clinical implication of VDAC1 in cervical cancer and found that the immunoreactivity was significantly stronger in cervical cancer tissues than that in normal tissues (p<0.001, median: 1.5 vs. 0.5, n=150 vs. 29; Figure 2A). This evidence concerns the gene VDAC1 and cervical carcinoma.